Cross-Taper Strategy for Switching from Olanzapine to Aripiprazole

Rationale and Protocol

The American Psychiatric Association recommends a gradual cross-titration approach over 1-4 weeks, starting aripiprazole at 10-15 mg daily while maintaining full-dose olanzapine for the first week, then reducing olanzapine by 25% every 3-7 days while monitoring for symptom exacerbation 1
Switching to aripiprazole may reduce metabolic side effects, such as weight gain, dyslipidemia, and insulin resistance, which are consistently associated with olanzapine, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 2

Start aripiprazole 10-15 mg once daily while maintaining the current full dose of olanzapine, as recommended by the American College of Psychiatrists 1, 3
Reduce olanzapine by 25% of the original dose after the first week, and maintain aripiprazole at 10-15 mg daily, according to the Mayo Clinic Proceedings 1, 5

Monitor positive psychotic symptoms, negative symptoms, extrapyramidal symptoms, and withdrawal effects from olanzapine during the cross-taper, as advised by the National Institute of Mental Health 1, 3, 5
Conduct metabolic monitoring, including weight, BMI, fasting glucose, and lipid panel, at baseline and 4-8 weeks post-switch, as recommended by the American Diabetes Association 2

For stable outpatients, use the 4-week gradual taper described above, as suggested by the American Psychiatric Association 1
If psychotic symptoms worsen during the switch, slow or pause the olanzapine taper, and consider increasing aripiprazole dose, according to the National Institute of Mental Health 1
If akathisia emerges with aripiprazole, consider reducing aripiprazole dose or adding propranolol or benztropine, as recommended by the American Academy of Neurology 3

Maintain aripiprazole at therapeutic dose for at least 4 weeks before assessing efficacy, as advised by the American College of Psychiatrists 1
Never abruptly discontinue olanzapine, as this significantly increases risk of withdrawal dyskinesias and rebound psychosis, according to the Mayo Clinic Proceedings 5